RLMD250516C2500
- 0.05
- 0.000.00%
Relmada Therapeutics Newsroom
Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment
Relmada Therapeutics: Initial Data From Phase 2 Study Of NDV-01 Shows Strong Clinical Activity In BCG-Naïve And BCG-Unresponsive Patients
Relmada Therapeutics to Hold a Virtual Meeting
Why ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
12 Health Care Stocks Moving In Wednesday's Intraday Session
Relmada Therapeutics To Present NDV-01 Data at AUA2025
Relmada Therapeutics Reports 2024 Financial Results and Strategic Progress
Earnings Call Summary | Relmada Therapeutics(RLMD.US) Q4 2024 Earnings Conference
Relmada Outlines Plans for NDV-01 Phase 2 Results Presentation and Sepranolone Development
RELMADA THERAPEUTICS Earnings Results: $RLMD Reports Quarterly Earnings
Relmada Therapeutics | 8-K: Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Relmada Therapeutics | 10-K: FY2024 Annual Report
Relmada Therapeutics 4Q Loss/Shr 62c >RLMD
Express News | Relmada Therapeutics: Expect Topline Phase 2 Data for Ndv-01 for High-Grade Non-Muscle Invasive Bladder Cancer (Hg-Nmibc)
Express News | Relmada Therapeutics Q4 2024 GAAP EPS $(0.62) Beats $(0.70) Estimate
Express News | Relmada Therapeutics Q4 Net Income USD -18.6 Million
Press Release: Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Earnings Scheduled For March 27, 2025
Express News | Relmada Therapeutics Inc -on March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC Filing
Insights Ahead: Relmada Therapeutics's Quarterly Earnings